'Quiet revolution' may herald new RNA therapeutics

Jan 21, 2007

Scientists at the University of Oxford have identified a surprising way of switching off a gene involved in cell division. The mechanism involves a form of RNA, a chemical found in cell nuclei, whose role was previously unknown, and could have implications for preventing the growth of tumour cells.

RNA plays an important and direct role in the synthesis of proteins, the building blocks of our bodies. However, scientists have known for some time that not all types of RNA are directly involved in protein synthesis. Now, in research funded by the Wellcome Trust and the Medical Research Council, a team of scientists has shown that one particular type of RNA plays a key role in regulating the gene implicated in control of tumour growth. The research is published online today in Nature.

The Human Genome Project identified about 34,000 genes responsible for producing proteins. The remaining part – in fact, most of the genome – constituted what was considered to be "junk" DNA with no function. However, latest estimates show that this "junk" DNA produces around half a million varieties of RNA of unknown functions.

"There's been a quiet revolution taking place in biology during the past few years over the role of RNA," says Dr Alexandre Akoulitchev, a Senior Research Fellow at the University of Oxford. "Scientists have begun to see 'junk' DNA as having a very important function. The variety of RNA types produced from this "junk" is staggering and the functional implications are huge."

The particular form of RNA that has been of interest to Dr Akoulitchev's team is involved in regulation of the dihydrofolate reductase gene (DHFR), determining whether the gene is "on" or "off". The DHFR gene produces an enzyme that controls thymine production, necessary in rapidly dividing cells.

"Inhibiting the DHFR gene could help prevent the growth of neoplastic cancerous cells, ordinary cells which develop into tumour cells, such as in prostate cancer cells," explains Dr Akoulitchev. "In fact, the first anti-cancer drug, Methotrexate, acts by binding and inhibiting the enzyme produced by this gene."

Dr Akoulitchev believes that understanding how we can use the RNA to switch off or inhibit DHFR and other genes may have important therapeutic implications for developing new anti-cancer treatments.

Source: Wellcome Trust

Explore further: Video of mini hearts and livers for "Body on a Chip" project update

Related Stories

The microscopic topography of ink on paper

1 hour ago

A team of Finnish scientists has found a new way to examine the ancient art of putting ink to paper in unprecedented 3-D detail. The technique could improve scientists' understanding of how ink sticks to ...

Harvesting energy from electromagnetic waves

1 hour ago

For our modern, technologically-advanced society, in which technology has become the solution to a myriad of challenges, energy is critical not only for growth but also, more importantly, survival. The sun ...

Scientists hold breath for comet lander to wake

1 hour ago

Europe's comet lander Philae has remained obstinately silent since a new bid was launched to communicate with it, mission chiefs said Tuesday, but chances for contact were improving daily.

Recommended for you

Technique could speed biologic drugs

4 hours ago

Antibodies are specific molecules that can lock onto a particular cellular structure to start, stop or otherwise temper a biological process. Because they are so specific, antibodies are at the forefront ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.